ALEC
Analyst Coverage
Cannabis Investor News in-house rating · cin-analyst-v1.0
Alector earns an Underweight rating at a 30.2 composite score, with low conviction of 1/5. The regulatory pillar leads at 49, supported by an 80 enforcement subscore, a 50 jurisdiction posture, and a 25 filing-cadence score. Market contributes 40, although unavailable institutional pricing prevents confirmation from current trading data. Editorial contributes 30, reflecting no newsroom or brief activity captured by CIN newsroom coverage. Fundamentals rank last at 10, driven by collapsing revenue, deeply negative margins, negative EBITDA, and limited cash-runway support. The pillar mix leaves the rating dependent on regulatory execution while operating performance and disclosure activity provide little counterweight.
Licensed fundamentals data show year-over-year revenue contracting by approximately 72%. Gross margin stands near negative 483%, while operating margin approaches negative 2,382%, placing both profitability measures at zero subscores. EBITDA is negative by approximately $127.5 million, and the 0.71 cash-burn ratio aligns with the stretched financial condition. Market capitalization is approximately $179 million, producing a 50.1 capitalization-tier subscore, but that contribution fails to offset the 15 cash-runway subscore. Primary regulatory filings show no dated latest filing, no recorded events across either the recent 90-day or 180-day periods, and no enforcement hits. That combination explains the relatively strong enforcement score but weak cadence score; inactivity supports compliance cleanliness without demonstrating active regulatory progress.
The clearest rerating catalyst sits inside the regulatory pillar, Alector’s strongest category. A fresh primary regulatory filing that establishes a current disclosure date and begins rebuilding cadence would add tangible evidence of execution, while continued clean enforcement data would preserve the pillar’s highest-scoring driver. Improved filing activity also could generate CIN newsroom coverage, lifting an editorial pillar currently anchored by zero captured hits. Fundamental improvement remains essential for a broader change in stance, given the severe revenue contraction, negative gross economics, negative operating margin, and ongoing EBITDA loss under a stretched financial condition. The single most important signal to watch is a new primary regulatory filing that converts regulatory inactivity into a measurable cadence improvement.
- IR / PR agency
- Argot Partners
- IR email
- [ir@alector.com](mailto:ir@alector.com)
- IR page
- Investor relations
- Headquarters
- 131 OYSTER POINT BLVD., SUITE 600, SOUTH SAN FRANCISCO, CA, 94080
- Phone
- 415-231-5660
- CEO
- Arnon Rosenthal, Ph.D.
- CFO
- Neil Berkley
- SEC CIK
- 1653087
- Website
- Company website
- Market cap
- $178.8M
- Enterprise value
- $6.2M
- Price to book
- 17.16
- Price to sales
- 9.71
- EV / EBITDA
- -8.40
- Revenue (TTM)
- $18.4M
- Gross profit (TTM)
- $-88.9M
- EBITDA
- $-127.5M
- Operating margin
- -2382.3%
- Profit margin
- 0.0%
- Rev growth YoY
- -71.5%
- Return on equity
- -238.8%
- Return on assets
- -25.7%
- EPS (TTM)
- $-1.19
- EPS est. current year
- $-0.88
- Wall St. target price
- $3.10
- Shares outstanding
- 111.0M
- Insider ownership
- 9.7%
- Institutional ownership
- 82.2%
- Beta
- 0.60
- Full-time employees
- 103
- GICS sector
- Healthcare
- GICS industry
- Biotechnology
- Annual report
- Latest 10-K
- Proxy statement
- Latest DEF 14A
- Filing portal
- SEC EDGAR
Help us keep coverage accurate. Submit an update for CIN editorial review.
Bullish and Bearish Analyst Opinions for ALEC (ALEC)
Cannabis Investor News aggregates analyst coverage, price targets, insider transactions, SEC filings, and financing activity for ALEC (ALEC), a cannabis-sector equity listed on OTCMKTS. Use this profile to compare bullish and bearish opinions, monitor Form 4 insider buys and sells, and review the latest quarterly results.
CIN editorial stance: Risk Elevated. Headwinds: deep drawdown. (0 bullish signals, 2 bearish signals.)
Historical Price Data
5-year weekly price history, intraday quotes, and 52-week range for ALEC are maintained by Cannabis Investor News and refreshed throughout the trading day.